Rapport Therapeutics, Inc. (RAPP) stock

RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30

$26.15+0.30 (+1.16%)

Close on Nov 13, 2026Market cap $1.25BP/E –Yield –

Rapport Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Rapport Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?